Mirum Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Mirum Pharmaceuticals, Inc. (MIRM) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $332.46 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $332.46M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $326.64M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $298.17M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $282.50M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $332.46M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $326.64M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $298.17M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $282.50M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $228.60M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $212.25M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $222.93M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $223.39M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $233.50M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $302.84M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $286.33M 10-K · filed 2026-02-25 |
| 2023-09-30 | $303.06M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $297.23M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $149.42M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $128.00M 10-K · filed 2026-02-25 |
| 2022-09-30 | $135.76M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $155.27M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $146.27M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $131.34M 10-K · filed 2025-02-26 |
| 2021-09-30 | $55.84M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $91.94M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $90.68M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $142.09M 10-K · filed 2024-03-15 |
| 2020-09-30 | $48.78M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $83.04M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $72.03M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $11.97M 10-K · filed 2022-03-09 |
| 2019-09-30 | $30.81M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $41.82M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $49.49M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $51.96M 10-K · filed 2021-03-09 |
| 2018-09-30 | $32.00K 10-Q · filed 2019-11-06 |
| 2018-05-02 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |